Comprehensive analyses of fatty acid metabolism-related lncRNA for ovarian cancer patients

Abstract Ovarian cancer (OC), as a disease with difficult early diagnosis and treatment and poor prognosis, is a hot spot in global cancer research. Recent studies have revealed the metabolic reprogramming of tumor cells and the important regulatory role of long non-coding RNAs (lncRNAs) in tumor progression, which may expand new directions for the treatment of OC. In this study, OC data profiles were downloaded from The Cancer Genome Atlas (TCGA). Eight key fatty acid metabolism-related lncRNAs were finally screened for building a risk scoring model by univariate/ multifactor and least absolute shrinkage and selection operator (LASSO) Cox regression. To make this risk scoring model more applicable to clinical work, we established a nomogram containing the clinical characteristics of OC patients after confirming that the model has good reliability and validity and the ability to distinguish patient prognosis. To further explore how these key lncRNAs are involved in OC progression, we explored their relationship with LUAD immune signatures and tumor drug resistance. Finally, to elucidate the roles of these lncRNAs at the molecular level, functional enrichment analysis was also performed. The structure shows that the risk scoring model established based on these 8 fatty acid metabolism-related lncRNAs has good reliability and validity and can better predict the prognosis of patients with different risks of OC, and LINC00861in these key RNAs may be a hub gene that affects the progression of OC and closely related to the sensitivity of current OC chemotherapy drugs. In addition, combined with immune signature analysis, we found that patients in the high-risk group are in a state of immunosuppression, and Tfh cells may play an important role in it, which may become an important site for future OC immunotherapy. In conclusion, we innovatively established a prognostic prediction model with excellent reliability and validity from the perspective of OC fatty acid metabolism reprogramming and lncRNA regulation and found new molecular/cellular targets for future OC treatment.